A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 Yrs) With Good Performance Status (PS < 2)
A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 Yrs) With Good Performance Status (PS < 2)
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving pemetrexed together with carboplatin and bevacizumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving pemetrexed together with carboplatin and bevacizumab works as first-line therapy in treating older patients with stage IIIB or stage IV non-small cell lung cancer.
OBJECTIVES:
Primary
Secondary
Tertiary
OUTLINE: This is a multicenter study.
Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease or partial or complete response after 6 courses may continue to receive pemetrexed disodium and bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
Tissue and blood samples are collected at baseline for pharmacogenetic analysis. Blood samples are used to evaluate functionally relevant polymorphisms in the genes that encode proteins involved in the transport and activation of pemetrexed disodium and in the genes that encode proteins involved in susceptibility to hypertension induced by bevacizumab. Tissue samples are used to evaluate expression and polymorphisms in pemetrexed disodium target genes (TS, DHFR, and GARFT).
Quality of life is assessed at baseline and periodically during study.
After completion of study therapy, patients are followed periodically for up to 5 years.
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed nonsquamous cell non-small cell lung cancer (NSCLC)
Stage IIIB (with pleural effusion) or IV disease
Squamous cell carcinomas not allowed
Clinically significant effusion (e.g., symptomatic pleural effusion or ascites) allowed provided it is drained before study treatment
Measurable disease, defined as ≥ 1 lesion with longest diameter ≥ 2.0 cm by conventional techniques or ≥ 1.0 cm by spiral CT scan
No symptomatic, untreated, or uncontrolled CNS metastases
Willing to enroll in NCCTG-N0392
PATIENT CHARACTERISTICS:
ECOG performance status 0-1
Life expectancy ≥ 12 weeks
ANC ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Hemoglobin ≥ 9 g/dL
Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin normal
AST and ALT ≤ 3 times ULN (≤ 5 times ULN if liver has tumor involvement)
Creatinine clearance ≥ 45 mL/min
Not pregnant or nursing
Fertile patients must use effective contraception during and for 3 months after completion of study treatment
Able to take folic acid, vitamin B_12 supplementation, or dexamethasone
Able to complete questionnaire(s) alone or with assistance
Willing to provide biologic specimens as required by the study
Willing to return to NCCTG participating center for follow-up
No clinically significant infection
No serious, nonhealing wounds, ulcers, or bone fractures
No seizure disorder
No second primary malignancy within the past 5 years, except for any of the following:
Carcinoma in situ of the cervix
Nonmelanomatous skin cancer
Low-grade (Gleason score ≤ 6) localized prostate cancer (no nodal involvement)
Previously treated stage I breast cancer
No concurrent severe and/or uncontrolled medical condition, including any of the following:
No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 12 months
No diverticulitis within the past 12 months
No stroke within the past 6 months
No significant traumatic injury within the past 8 weeks
Not at greater than normal risk of bleeding
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
No prior radiotherapy to > 25% of bone marrow
More than 2 weeks since prior radiotherapy and recovered (alopecia allowed)
At least 2 weeks since prior WBRT
At least 3 days since prior gamma knife radiosurgery (without WBRT) for brain metastases
More than 4 weeks since prior administration of live or attenuated viral vaccine
More than 8 weeks since prior major surgery (e.g., laparotomy) or open biopsy (> 4 weeks since minor surgery)
No prior chemotherapy or systemic therapy for advanced lung cancer, except neoadjuvant or adjuvant chemotherapy
No NSAID's 2 days prior to (5 days for long-acting NSAID's), the day of, and 2 days following protocol treatment
More than 12 months since prior neoadjuvant therapy, adjuvant therapy, systemic chemotherapy, chemoradiotherapy, immunotherapy, or biologic therapy
No concurrent anticoagulants
Grand Junction, Colorado 81502, United States
Hartford, Connecticut 06105, United States
Ottawa, Illinois 61350, United States
Peoria, Illinois 61615, United States
Beech Grove, Indiana 46107, United States
La Porte, Indiana 46350, United States
Des Moines, Iowa 50309, United States
Des Moines, Iowa 50314, United States
Wichita, Kansas 67214, United States
Dearborn, Michigan 48123-2500, United States
Grosse Pointe Woods, Michigan 48236, United States
Minneapolis, Minnesota 55407, United States
Robbinsdale, Minnesota 55422-2900, United States
Billings, Montana 59101, United States
Missoula, Montana 59807, United States
Sioux Falls, South Dakota 57117-5039, United States
Green Bay, Wisconsin 54301-3526, United States
Manitowoc, Wisconsin 54221-1450, United States